Julie Hang, PhDAssociate Director, PD Downstream at Sutro Biopharma
Julie Hang, PhD, is an associate director of Downstream Process Development at Sutro BioPharma. The group is responsible for developing manufacturing process of antibodies and therapeutic proteins for the cell-free expression system and antibody-drug conjugation. Dr. Hang led the team to enable an antibody purification platform and implemented it into multiple cGMP clinical productions from cell-free expression at Sutro. She provided strategies for purification process design and process improvement, and directed scale-up, process documentations, technology transfer, and manufacturing support. Dr. Hang has 18+ years industry experience on protein production and protein chemistry of therapeutics. Prior to Sutro, Dr. Hang led a team at Genentech in 2012 - 2016 to implement purification and conjugation expertise for therapeutic antibodies to be advanced into clinical trials, and evaluated the developability of new biologics for cancer immunology and ophthalmology indications. Before joining Genentech, she was a group leader on the downstream process development of novel vaccines at MedImmune. She was a cross-functional project leader at Roche Palo Alto on proteins encompassing from target identification to IND regulatory submission. Dr. Hang authored and co-authored 20+ peer-reviewed publications and 20+ process development documents. She received her PhD from The University of Iowa and completed postdoctoral studies at Eli Lilly and Company.